论文部分内容阅读
目的:判断细胞角蛋白19(cytokeratin19,CK19)作为循环肿瘤细胞的标志物的意义,探讨在肾癌病人外周血中CK19的表达情况和临床价值,并观察汉族与维吾尔族肾癌患者之间循环肿瘤细胞的差异。方法:50例肾癌病人设为病例组,健康体检人群50例设为对照组,对上述两组人群应用流式细胞仪技术检测外周血中CK19的表达水平;并探讨肾癌病人外周血CK19的表达与肾癌病理分类、病理分期及组织学分级之间的关系;比较20例汉族肾细胞癌患者及20例维吾尔族肾癌患者外周血中CK19的差异表达情况。结果:组间比较,50例对照组中无阳性,50例肾癌患者组中24例阳性;组内比较,不同肾癌病理分类之间CK19表达差异没有统计学意义(P>0.05),不同肾癌病理分期及组织学分级之间CK19表达差异具有有统计学意义(P<0.05)。维吾尔族与汉族两个不同民族肾癌之间的血清循环肿瘤细胞存在着较明显差异(P<0.05)。结论:在肾癌患者外周血中的CK19可以初步判断循环肿瘤细胞的水平,对早期肾癌的诊断、预测具有一定的意义,值得进一步探索和研究,维吾尔族肾癌与汉族肾癌患者之间循环肿瘤细胞可能存在差异。
Objective: To determine the significance of cytokeratin 19 (CK19) as a marker of circulating tumor cells and to explore the expression and clinical value of CK19 in the peripheral blood of patients with renal cell carcinoma and to observe the relationship between circulating renal cell carcinoma of Han and Uygur patients Differences in tumor cells. Methods: Fifty cases of renal cell carcinoma were selected as case group and 50 healthy control group as control group. Flow cytometry was used to detect the expression of CK19 in peripheral blood of the two groups. The correlation between the expression of CK19 and the pathological classification, pathological staging and histological grade of renal cell carcinoma was analyzed. The expression of CK19 in 20 cases of Han renal cell carcinoma and 20 cases of Uygur kidney cancer was analyzed. Results: There was no positive result in 50 cases of control group and 24 cases in 50 cases of renal cell carcinoma group. There was no significant difference in the expression of CK19 among different groups (P> 0.05) The difference of CK19 expression between pathological stage and histological grade of renal cell carcinoma was statistically significant (P <0.05). Serum circulating tumor cells between Uygur and Han ethnic groups were significantly different (P <0.05). Conclusion: CK19 in peripheral blood of patients with renal cell carcinoma can be used to determine circulating tumor cells initially, which is of significance for the diagnosis and prognosis of early stage renal cell carcinoma. It is worth further exploration and research. Between Uighur kidney cancer and Han patients with renal cell carcinoma Circulating tumor cells may be different.